Navigation Links
YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
Date:12/12/2008

MISSISSAUGA, Canada, Dec. 12 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that its majority-owned subsidiary CIMYM BioSciences Inc. received a milestone payment from its licensee Innogene Kalbiotech Ltd (IGK) in recognition of the recent marketing approval of nimotuzumab in the Philippines and Indonesia. IGK is the biotech subsidiary of P.T Kalbe Farma Tbk (Jakarta, Indonesia), one of the largest pharmaceutical companies in the region with more than 8,100 employees and annual revenues exceeding US$300 million.

"With the addition of the Philippines and Indonesia, nimotuzumab has now received marketing approval in twelve countries. Demand for novel medicines is growing rapidly in the emerging markets of the world and nimotuzumab is well positioned to become a key cancer therapeutic in these territories due to its unique safety profile compared with the other EGFR-targeting drugs," said David Allan, Chairman and CEO of YM BioSciences. "Highlighting this competitive advantage, reports have increased in frequency describing toxicities associated with the combination of the other EGFR drugs and radiation. In addition to Grade III/IV rash, Grade IV radiation dermatitis, another serious and debilitating toxicity, has recently been reported affecting approximately 28% of patients treated with a currently marketed EGFR-targeting antibody together with radiation while absent in patients treated with radiation alone."

In none of the clinical trials of nimotuzumab to date, to YM's knowledge, have any of the patients developed Grade III/IV acneiform rash, also a severe and dose-limiting side-effect observed in all of the other antibodies and with small molecules targeting the EGF tyrosine kinase signaling pathway. Unrelated to the rash, Grade III/IV radiation dermatitis is a severe toxici
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
2. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
3. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
4. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
5. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
6. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
9. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
10. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 According to ... Composition of Material, Application (Healthcare, Homeland security, Industrial ... (Personal Instrument, Hand-Held Instruments, Fixed, and Installed Instruments) ... 2013 - 2020", published by MarketsandMarkets, the Scintillator Market is ... from 2014 to 2020, and reach $479.16 Million ...
(Date:7/11/2014)... 11, 2014  Australian drug delivery company, Phosphagenics Limited ... raised A$19.3 million via a placement of A$16.3 million ... the U.S., Asia and ... share purchase plan (SPP) to be offered to existing ... in two tranches. "This capital raising positions ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... Nov. 1, 2010 The National Quality Forum ... of its eight member councils.   ... to improving the quality of American healthcare by ... endorsing national consensus standards for measuring and publicly ...
... Octapharma AG , one of ... and Octapharma USA today announced that patients ... a multi-center study that is researching the use of ... human cell line (Human-cl rhFVIII). Researchers are investigating Human-cl ...
Cached Medicine Technology:National Quality Forum Members Elect New Council Leaders 2Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line 2Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line 3
(Date:7/13/2014)... 2014 Athletes with a certain genetic ... concussions, according to research presented today at the American ... Meeting. The research marks the first of its kind ... known physical events that occur after a head injury. ... allele in the (GT)n genotype were four times more ...
(Date:7/13/2014)... Rico (PRWEB) July 13, 2014 ... of Famer, Chris Mullin, will be the featured guest ... July 26th in Puerto Rico. Attendees will learn ... will participate in two exhibition basketball games and perform ... ultimate supplier of health- and energy-boosting supplements , ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Epidemiologists forecast ... in the 6MM, from 8,062 diagnosed incident cases in ... an Annual Growth Rate (AGR) of 4.35%, during the ... highest number of diagnosed incident cases of aGVHD in ... will have the lowest number of diagnosed incident cases ...
(Date:7/13/2014)... According to the Kidney Disease Solution book ... step guide on what to do to eliminate the root ... writes in its review that readers can easily learn what ... their kidney health. Vkool also informs in its Kidney Disease ... damaged kidney functions naturally. The book consists of a collection ...
(Date:7/13/2014)... Beverly Hills, California (PRWEB) July 13, 2014 ... Champion Danny Musico has formed a promotional partnership with ... revolutionary plant based Omega-3 EPA supplement . The ... Musico is a celebrity fitness trainer , actor, ... As Hollywood’s go-to trainer for A-List celebrities, he has ...
Breaking Medicine News(10 mins):Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
... 2 Hess Corporation will present two $50,000 checks -- one ... other to Children,s Hospital Boston,s Trauma Program -- as part of ... opening day. Aric Morrison, a Hess Retail regional director, will present ... promised to donate $500 for every home run hit during a ...
... in ongoing program to prevent adverse health events ... Thirty-one Minnesota hospitals recently were named winners of the ... awards honor hospitals, efforts to prevent four types of ... invasive procedures and foreign objects retained during labor and ...
... CHICAGO, Oct. 2 Beginning October 1st, The Peninsula Chicago ... Cancer Awareness Month and several cancer research and education organizations. ... by breast cancer in some way and this is why ... said Maria Zec, general manager of The Peninsula Chicago. "In ...
... devastation of the 1918-1919 influenza pandemic is well known, but ... death toll: the misuse of aspirin. Appearing in the November ... the article sounds a cautionary note as present day concerns ... dosing levels used to treat patients during the 1918-1919 pandemic ...
... more improves outcomes, study shows , FRIDAY, Oct. 2 ... bypass surgery can be used to reverse morbid obesity ... U.S. researchers say. , Their study included 61 teens ... Hospital Medical Center. One year after surgery, overall body ...
... lead to better treatments, researchers say, , FRIDAY, Oct. ... stomach cancers could lead to more effective treatments and ... say. , For a study published online Oct. 1 ... stomach tumors from people in Australia, Singapore and Great ...
Cached Medicine News:Health News:Hess Home Run Campaign a Hit for Kids with Medical Needs 2Health News:Hess Home Run Campaign a Hit for Kids with Medical Needs 3Health News:Thirty-one Minnesota Hospitals Win Patient Safety Awards 2Health News:The Peninsula Chicago Gives Back During Breast Cancer Awareness Month 2Health News:Delaying Weight-Loss Surgery May Leave Teens at Risk 2Health News:New Classification Proposed for Stomach Cancers 2
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
... Macula Plus® 5.5 is ... of the optic nerve ... it with your binocular ... choroidal neovascular membranes, macular ...
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
The iQ200 Automated Urinalysis System (iQ System) is a user-friendly, bench top, fully automated system that performs complete urinalyses on unspun specimens; simply load, press START and walk away....
Medicine Products: